Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IM-01
- Development stage
- Phase 2
- Lead developer
- ImmuniMed
- Modality
- Antibody-Based Therapeutics
01
Overview
IM-01 is an investigational egg-derived polyclonal antibody developed by ImmuniMed Inc. for the treatment of mild-moderate Clostridium difficile infection (CDI). It functions by reacting with C. difficile toxin, C. difficile bacteria, and spores, thereby neutralizing the toxin and inhibiting the growth of both vegetative forms and spores of C. difficile.
- Brand names
- CDiffFYX
- Other names
- egg-derived polyclonal antibodiesegg-derived anti-C. difficile polyclonal antibodies
02
Targets
Clostridioides difficile sporesTcdA (Clostridioides difficile toxin A)TcdB (Clostridioides difficile large clostridial toxin family)
Beyond the preview
Go deeper on IM-01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IM-01.